

Huldrych F Gunthard

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2942086/huldrych-f-gunthard-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

419
papers

23,118
citations

79
h-index

140
g-index

471
ext. papers

26,305
ext. citations

7.3
avg, IF

6.18
L-index

#	Paper	IF	Citations
419	Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting.. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofac029	1	1
418	Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV.. <i>Scientific Reports</i> , 2022 , 12, 577	4.9	3
417	A highly virulent variant of HIV-1 circulating in the Netherlands.. <i>Science</i> , 2022 , 375, 540-545	33.3	5
416	Phylogenetic estimation of the viral fitness landscape of HIV-1 set-point viral load.. <i>Virus Evolution</i> , 2022 , 8, veac022	3.7	
415	Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study. <i>Journal of Infectious Diseases</i> , 2021 , 224, 1198-1208	7	3
414	Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRIL-196 plus BRIL-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.. <i>Lancet Infectious Diseases</i> , 2021 ,	25.5	16
413	Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization. <i>Nature Communications</i> , 2021 , 12, 6705	17.4	1
412	Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity. <i>Nature Communications</i> , 2021 , 12, 6703	17.4	2
411	A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty [®] and COVID-19 mRNA Vaccine Moderna [®] . <i>Trials</i> , 2021 , 22, 724	2.8	1
410	Assessing relative COVID-19 mortality during the second wave: a prospective Swiss population-based study. <i>BMJ Open</i> , 2021 , 11, e051164	3	1
409	Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study. <i>PLoS Computational Biology</i> , 2021 , 17, e1009529	5	0
408	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021 , 73, e2323-e2333	11.6	5
407	Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma. <i>Haematologica</i> , 2021 , 106, 2233-2241	6.6	1
406	A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021 , 73, e2194-e2202	11.6	13
405	Telomere Length, Traditional Risk Factors, Factors Related to Human Immunodeficiency Virus (HIV) and Coronary Artery Disease Events in Swiss Persons Living With HIV. <i>Clinical Infectious Diseases</i> , 2021 , 73, e2070-e2076	11.6	4
404	Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment. <i>Clinical Infectious Diseases</i> , 2021 , 73, e2134-e2141	11.6	3
403	Do we cause false positives? An experimental series on droplet or airborne SARS-CoV-2 contamination of sampling tubes during swab collection in a test center. <i>Antimicrobial Resistance and Infection Control</i> , 2021 , 10, 51	6.2	0

402	Assessing relative COVID-19 mortality: a Swiss population-based study. <i>BMJ Open</i> , 2021 , 11, e042387	3	5
401	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study. <i>Annals of Internal Medicine</i> , 2021 , 174, 758-767	8	22
400	HIV-1 integration sites in CD4+ T cells during primary, chronic, and late presentation of HIV-1 infection. <i>JCI Insight</i> , 2021 , 6,	9.9	1
399	High Efficacy of Saliva in Detecting SARS-CoV-2 by RT-PCR in Adults and Children. <i>Microorganisms</i> , 2021 , 9,	4.9	11
398	Impact of Delaying Antiretroviral Treatment during Primary HIV Infection on Telomere Length. <i>Journal of Infectious Diseases</i> , 2021 ,	7	1
397	Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 4455-4460	3.8	
396	Coronary Artery Disease-Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1597-1604	11.6	0
395	Phylogenetic Cluster Analysis Identifies Virological and Behavioral Drivers of Human Immunodeficiency Virus Transmission in Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2021 , 72, 2175-2183	11.6	2
394	The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021 , 72, 1413-1421	11.6	0
393	Assessing the potential impact of transmission during prolonged viral shedding on the effect of lockdown relaxation on COVID-19. <i>PLoS Computational Biology</i> , 2021 , 17, e1008609	5	2
392	Dissemination of is associated to a null variant that limits antigen exchange via trafficking extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2021 , 10, e12046	16.4	2
391	Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis. <i>Nature Communications</i> , 2021 , 12, 1219	17.4	
390	The influence of human genetic variation on Epstein-Barr virus sequence diversity. <i>Scientific Reports</i> , 2021 , 11, 4586	4.9	2
389	Emergence of Human Immunodeficiency Virus-1 Drug Resistance During the 3-Month World Health Organization-Recommended Enhanced Adherence Counseling Period in the CART-1 Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab046	1	
388	Increasing Frequency and Transmission of HIV-1 Non-B Subtypes among Men Who Have Sex with Men in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2021 ,	7	1
387	Identifying and Characterizing Trans women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	1
386	Reduced Relative Sensitivity of the Elecsys SARS-CoV-2 Antigen Assay in Saliva Compared to Nasopharyngeal Swabs. <i>Microorganisms</i> , 2021 , 9,	4.9	3
385	Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C. <i>PLoS Computational Biology</i> , 2021 , 17, e1008363	5	1

384	Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 88, 61-69	3.1	2
383	Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. <i>Lancet HIV</i> , 2021 , 8, e711-e722	7.8	2
382	Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab032	1	5
381	The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	5
380	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). <i>International Journal of Epidemiology</i> , 2021 ,	7.8	6
379	Clusters of Sexual Behavior in Human Immunodeficiency Virus-positive Men Who Have Sex With Men Reveal Highly Dissimilar Time Trends. <i>Clinical Infectious Diseases</i> , 2020 , 70, 416-424	11.6	2
378	Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. <i>Nature Communications</i> , 2020 , 11, 5542	17.4	2
377	Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2020 , 222, 637-645	7	10
376	Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV. <i>Journal of Mass Spectrometry</i> , 2020 , 55, e4506	2.2	7
375	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial. <i>PLoS Medicine</i> , 2020 , 17, e1003421	11.6	7
374	Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study: 1980-2018. <i>Antiviral Therapy</i> , 2020 , 25, 43-54	1.6	1
373	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV. <i>PLoS Biology</i> , 2020 , 18, e3000963	9.7	0
372	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. <i>PLoS ONE</i> , 2020 , 15, e0243625	3.7	0
371	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. <i>PLoS Medicine</i> , 2020 , 17, e1003397	11.6	1
370	561. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S345-S346	1	3
369	Increased CHIP Prevalence Amongst People Living with HIV 2020 ,		5
368	Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: Kinetics and anal cancer risk prediction. <i>International Journal of Cancer</i> , 2020 , 147, 757-765	7.5	3
367	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 1651-1669	27.4	128

366	Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation. <i>Viruses</i> , 2020 , 12,	6.2	1
365	Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 85, 517-524	3.1	3
364	Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 85, 227-232	3.1	3
363	Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients. <i>Clinical Infectious Diseases</i> , 2020 , 70, 297-303	11.6	9
362	Self-reported Neurocognitive Impairment in People Living With Human Immunodeficiency Virus (HIV): Characterizing Clusters of Patients With Similar Changes in Self-reported Neurocognitive Impairment, 2013-2017, in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2020 , 71, 637-644	11.6	2
361	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV 2020 , 18, e3000963		
360	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV 2020 , 18, e3000963		
359	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV 2020 , 18, e3000963		
358	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV 2020 , 18, e3000963		
357	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV 2020 , 18, e3000963		
356	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV 2020 , 18, e3000963		
355	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study 2020 , 17, e1003397		
354	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study 2020 , 17, e1003397		
353	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study 2020 , 17, e1003397		
352	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study 2020 , 17, e1003397		
351	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPLERIV trial 2020 , 17, e1003421		
350	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPLERIV trial 2020 , 17, e1003421		
349	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPLERIV trial 2020 , 17, e1003421		

348	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPLERIV trial 2020, 17, e1003421		
347	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPLERIV trial 2020, 17, e1003421		
346	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPLERIV trial 2020, 17, e1003421		
345	Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2690-2697	5.1	11
344	Two Years of Viral Metagenomics in a Tertiary Diagnostics Unit: Evaluation of the First 105 Cases. <i>Genes</i> , 2019, 10,	4.2	29
343	Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells. <i>Journal of Experimental Medicine</i> , 2019, 216, 2071-2090	16.6	14
342	The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2019, 24, 343-353	1.6	2
341	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , 2019, 393, 2428-2438	40	363
340	A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases. <i>Journal of Infectious Diseases</i> , 2019, 220, 244-253	7.3	4
339	Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection. <i>Journal of Infectious Diseases</i> , 2019, 220, 254-265	7	10
338	Reply to Ambrosioni et al. <i>Clinical Infectious Diseases</i> , 2019, 68, 1977-1978	11.6	
337	High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2019, 68, 569-576	11.6	22
336	Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel. <i>Clinical Infectious Diseases</i> , 2019, 68, 177-187	11.6	98
335	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz330	1	16
334	Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. <i>Nature Communications</i> , 2019, 10, 3193	17.4	50
333	Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017. <i>Journal of the International AIDS Society</i> , 2019, 22, e25339	5.4	11
332	2019 update of the drug resistance mutations in HIV-1. <i>Topics in Antiviral Medicine</i> , 2019, 27, 111-121	3.2	83
331	High Number of Potential Transmitters Revealed in a Population-based Systematic Hepatitis C Virus RNA Screening Among Human Immunodeficiency Virus-infected Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2019, 68, 561-568	11.6	9

330	Changing Trends in International Versus Domestic HCV Transmission in HIV-Positive Men Who Have Sex With Men: A Perspective for the Direct-Acting Antiviral Scale-Up Era. <i>Journal of Infectious Diseases</i> , 2019 , 220, 91-99	7	13
329	IL-4 polymorphism influences susceptibility to <i>Pneumocystis jirovecii</i> pneumonia in HIV-positive patients. <i>Aids</i> , 2019 , 33, 1719-1727	3.5	6
328	Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 82, 314-320	3.1	4
327	HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 81, 508-515	3.1	
326	Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial. <i>Clinical Infectious Diseases</i> , 2019 , 69, 1489-1497	11.6	8
325	Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 468-472	5.1	6
324	High Rates of Subsequent Asymptomatic Sexually Transmitted Infections and Risky Sexual Behavior in Patients Initially Presenting With Primary Human Immunodeficiency Virus-1 Infection. <i>Clinical Infectious Diseases</i> , 2018 , 66, 735-742	11.6	18
323	MRI and PET-CT Failed to Differentiate Between Hepatic Malignancy and Brucelloma. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy052	1	1
322	Low prevalence of transmitted HIV-1 drug resistance detected by a dried blood spot (DBS)-based next-generation sequencing (NGS) method in newly diagnosed individuals in Cameroon in the years 2015-16. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1917-1929	5.1	13
321	Development of a high-throughput bead based assay system to measure HIV-1 specific immune signatures in clinical samples. <i>Journal of Immunological Methods</i> , 2018 , 454, 48-58	2.5	10
320	No Effect of Pegylated Interferon- α on Total HIV-1 DNA Load in HIV-1/HCV Coinfected Patients. <i>Journal of Infectious Diseases</i> , 2018 , 217, 1883-1888	7	8
319	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 379-396	27.4	390
318	CD161 Defines a Functionally Distinct Subset of Pro-Inflammatory Natural Killer Cells. <i>Frontiers in Immunology</i> , 2018 , 9, 486	8.4	49
317	Spontaneous reactivation of latent HIV-1 promoters is linked to the cell cycle as revealed by a genetic-insulators-containing dual-fluorescence HIV-1-based vector. <i>Scientific Reports</i> , 2018 , 8, 10204	4.9	5
316	Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics. <i>PLoS Pathogens</i> , 2018 , 14, e1006895	7.6	30
315	Antibacterial effects of antiretrovirals, potential implications for microbiome studies in HIV. <i>Antiviral Therapy</i> , 2018 , 23, 91-94	1.6	13
314	Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. <i>Aids</i> , 2018 , 32, 327-335	3.5	11
313	On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: A mathematical modelling study. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 10-18	3.4	14

312	Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. <i>Virus Evolution</i> , 2018 , 4, vey024	3.7	16
311	Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma. <i>Aids</i> , 2018 , 32, 2759-2765	3.5	5
310	Baseline Genotype Testing to Assess Drug Resistance Before Beginning HIV Treatment-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 2154	27.4	
309	Easy and accurate reconstruction of whole HIV genomes from short-read sequence data with shiver. <i>Virus Evolution</i> , 2018 , 4, vey007	3.7	38
308	Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. <i>Molecular Biology and Evolution</i> , 2018 , 35, 27-37	8.3	19
307	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. <i>Nature</i> , 2018 , 561, 406-410	50.4	37
306	The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy078	1	5
305	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. <i>Journal of Experimental Medicine</i> , 2018 , 215, 1589-1608	16.6	23
304	HIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient Clinic. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 78, 566-573	3.1	7
303	OMIP-047: High-Dimensional phenotypic characterization of B cells. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018 , 93, 592-596	4.6	12
302	and Proteome Analysis of Human Immunodeficiency Virus (HIV)-1-infected, Human CD4 T Cells. <i>Molecular and Cellular Proteomics</i> , 2017 , 16, S108-S123	7.6	15
301	Mining for pairs: shared clinic visit dates identify steady HIV-positive partnerships. <i>HIV Medicine</i> , 2017 , 18, 667-676	2.7	2
300	Prescription of Postexposure Prophylaxis for HIV-1 in the Emergency Room: Correct Transmission Risk Assessment Remains Challenging. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 74, 359-366	3.1	5
299	Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2017 , 64, 1275-1278	11.6	12
298	Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. <i>EBioMedicine</i> , 2017 , 18, 225-235	8.8	25
297	Evaluation of the Predictive Potential of the Short Acute Retroviral Syndrome Severity Score for HIV-1 Disease Progression in Individuals With Acute HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 74, e114-e117	3.1	2
296	Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. <i>Aids</i> , 2017 , 31, 427-436	3.5	123
295	Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals. <i>Medicine (United States)</i> , 2017 , 96, e5849	1.8	25

294	Human papillomavirus antibody response following HAART initiation among MSM. <i>Aids</i> , 2017 , 31, 561-569	5	9
293	Adverse events of raltegravir and dolutegravir. <i>Aids</i> , 2017 , 31, 1853-1858	3.5	68
292	Reply to correspondence 'Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a "stochastic" process' by Gonzalez et al., <i>Retrovirology</i> 2017. <i>Retrovirology</i> , 2017 , 14, 14	3.6	2
291	Parent-offspring regression to estimate the heritability of an HIV-1 trait in a realistic setup. <i>Retrovirology</i> , 2017 , 14, 33	3.6	8
290	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. <i>Journal of Hepatology</i> , 2017 , 66, 297-303	13.4	58
289	Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. <i>ELife</i> , 2017 , 6,	8.9	13
288	Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe. <i>PLoS Biology</i> , 2017 , 15, e2001855	9.7	21
287	Phylodynamics on local sexual contact networks. <i>PLoS Computational Biology</i> , 2017 , 13, e1005448	5	11
286	Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality. <i>PLoS Pathogens</i> , 2017 , 13, e1006235	7.6	22
285	Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters. <i>PLoS Pathogens</i> , 2017 , 13, e1006313	7.6	15
284	Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants. <i>Clinical Microbiology and Infection</i> , 2016 , 22, 191-200	9.5	18
283	Monocyte-derived macrophages exhibit distinct and more restricted HIV-1 integration site repertoire than CD4(+) T cells. <i>Scientific Reports</i> , 2016 , 6, 24157	4.9	13
282	Large-scale inference of conjunctive Bayesian networks. <i>Bioinformatics</i> , 2016 , 32, i727-i735	7.2	10
281	Identification of Siglec-1 null individuals infected with HIV-1. <i>Nature Communications</i> , 2016 , 7, 12412	17.4	18
280	A Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and Switzerland. <i>Scientific Reports</i> , 2016 , 6, 32251	4.9	11
279	Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. <i>Retrovirology</i> , 2016 , 13, 62	3.6	31
278	CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. <i>Medicine (United States)</i> , 2016 , 95, e5094	1.8	19
277	Immune recovery in HIV-infected patients after <i>Candida</i> esophagitis is impaired despite long-term antiretroviral therapy. <i>Aids</i> , 2016 , 30, 1923-33	3.5	5

276	Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis. <i>Journal of Infectious Diseases</i> , 2016 , 214, 599-606	7	26
275	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. <i>Lancet Infectious Diseases</i> , 2016 , 16, 565-575	25.5	175
274	A Comprehensive Analysis of Primer IDs to Study Heterogeneous HIV-1 Populations. <i>Journal of Molecular Biology</i> , 2016 , 428, 238-250	6.5	19
273	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1352-60	5.1	3
272	Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. <i>Clinical Infectious Diseases</i> , 2016 , 62, 1310-1317	11.6	39
271	HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2016 , 62, 115-122	11.6	43
270	In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid. <i>Drug Metabolism and Disposition</i> , 2016 , 44, 151-61	4	21
269	2017 Update of the Drug Resistance Mutations in HIV-1. <i>Topics in Antiviral Medicine</i> , 2016 , 24, 132-133	3.2	124
268	Assessment of Overlap of Phylogenetic Transmission Clusters and Communities in Simple Sexual Contact Networks: Applications to HIV-1. <i>PLoS ONE</i> , 2016 , 11, e0148459	3.7	20
267	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 191-210	27.4	449
266	Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland. <i>Scientific Reports</i> , 2016 , 6, 27580	4.9	14
265	Privacy-preserving genomic testing in the clinic: a model using HIV treatment. <i>Genetics in Medicine</i> , 2016 , 18, 814-22	8.1	25
264	Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2016 , 214, 399-402	7	31
263	Determinants of HIV-1 broadly neutralizing antibody induction. <i>Nature Medicine</i> , 2016 , 22, 1260-1267	50.5	99
262	Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. <i>HIV Medicine</i> , 2015 , 16, 297-306	2.7	8
261	Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds. <i>PLoS Pathogens</i> , 2015 , 11, e1004722	7.6	52
260	Estimating the dynamics and dependencies of accumulating mutations with applications to HIV drug resistance. <i>Biostatistics</i> , 2015 , 16, 713-26	3.7	2
259	The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals. <i>Journal of Infectious Diseases</i> , 2015 , 212, 578-84	7	17

258	Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. <i>Gut</i> , 2015 , 64, 813-9	19.2	53
257	Cluster of Leptospirosis Acquired Through River Surfing in Switzerland. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv102	1	9
256	Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3323-31	5.1	5
255	The orientation of HIV-1 gp120 binding to the CD4 receptor differentially modulates CD4+ T cell activation. <i>Journal of Immunology</i> , 2015 , 194, 637-49	5.3	8
254	Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2015 , 20, 165-75	1.6	26
253	Molecular Analyses Define V β .2-J β 3+ MAIT Cell Depletion in HIV Infection: A Case-Control Study. <i>Medicine (United States)</i> , 2015 , 94, e1134	1.8	18
252	Simultaneously estimating evolutionary history and repeated traits phylogenetic signal: applications to viral and host phenotypic evolution. <i>Methods in Ecology and Evolution</i> , 2015 , 6, 67-82	7.7	15
251	Gut commensal microbes do not represent a dominant antigenic source for continuous CD4+ T-cell activation during HIV-1 infection. <i>European Journal of Immunology</i> , 2015 , 45, 3107-13	6.1	1
250	Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. <i>HIV Medicine</i> , 2015 , 16, 599-607	2.7	5
249	The impact of vaccination on the breadth and magnitude of the antibody response to influenza A viruses in HIV-infected individuals. <i>Aids</i> , 2015 , 29, 1803-10	3.5	6
248	Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality. <i>Aids</i> , 2015 , 29, 2195-200	3.5	47
247	Frequency and Spectrum of Unexpected Clinical Manifestations of Primary HIV-1 Infection. <i>Clinical Infectious Diseases</i> , 2015 , 61, 1013-21	11.6	56
246	A framework for inferring fitness landscapes of patient-derived viruses using quasispecies theory. <i>Genetics</i> , 2015 , 199, 191-203	4	22
245	Increases in Condomless Sex in the Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv077		26
244	Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. <i>BMC Infectious Diseases</i> , 2015 , 15, 382	4	21
243	Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 930-40	5.1	86
242	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. <i>Journal of Infectious Diseases</i> , 2015 , 212, 28-38	7	49
241	Subacute, tetracycline-responsive, granulomatous osteomyelitis in an adult man, consistent with Q fever infection. <i>BMJ Case Reports</i> , 2015 , 2015,	0.9	2

240	HIV-1 RNAs are Not Part of the Argonaute 2 Associated RNA Interference Pathway in Macrophages. <i>PLoS ONE</i> , 2015 , 10, e0132127	3.7	12
239	2015 Update of the Drug Resistance Mutations in HIV-1. <i>Topics in Antiviral Medicine</i> , 2015 , 23, 132-41	3.2	96
238	Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo. <i>Journal of Virology</i> , 2014 , 88, 763-7	6.6	25
237	Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide. <i>Journal of Infectious Diseases</i> , 2014 , 210, 1555-61	7	13
236	Social meets molecular: Combining phylogenetic and latent class analyses to understand HIV-1 transmission in Switzerland. <i>American Journal of Epidemiology</i> , 2014 , 179, 1514-25	3.8	21
235	Prevalence and predictors for homo- and heterosubtypic antibodies against influenza A virus. <i>Clinical Infectious Diseases</i> , 2014 , 59, 1386-93	11.6	8
234	Role of microRNA modulation in the interferon- β /tribavirin suppression of HIV-1 in vivo. <i>PLoS ONE</i> , 2014 , 9, e109220	3.7	7
233	High-throughput sequencing of human immunoglobulin variable regions with subtype identification. <i>PLoS ONE</i> , 2014 , 9, e111726	3.7	22
232	A novel Acute Retroviral Syndrome Severity Score predicts the key surrogate markers for HIV-1 disease progression. <i>PLoS ONE</i> , 2014 , 9, e114111	3.7	12
231	Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation. <i>Retrovirology</i> , 2014 , 11, 75	3.6	14
230	Disentangling human tolerance and resistance against HIV. <i>PLoS Biology</i> , 2014 , 12, e1001951	9.7	36
229	Full-length haplotype reconstruction to infer the structure of heterogeneous virus populations. <i>Nucleic Acids Research</i> , 2014 , 42, e115	20.1	97
228	Quantifying the turnover of transcriptional subclasses of HIV-1-infected cells. <i>PLoS Computational Biology</i> , 2014 , 10, e1003871	5	16
227	Using an epidemiological model for phylogenetic inference reveals density dependence in HIV transmission. <i>Molecular Biology and Evolution</i> , 2014 , 31, 6-17	8.3	43
226	New onset of kaposi sarcoma in a human immunodeficiency virus-1-infected homosexual man, despite early antiretroviral treatment, sustained viral suppression, and immune restoration. <i>Open Forum Infectious Diseases</i> , 2014 , 1, ofu005	1	6
225	CD8+ T cells are activated in an antigen-independent manner in HIV-infected individuals. <i>Journal of Immunology</i> , 2014 , 192, 1732-44	5.3	35
224	Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients. <i>Aids</i> , 2014 , 28, 2231-9	3.5	19
223	Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 410-25	27.4	384

222	Treatment-naïve individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2014 , 58, 285-94	11.6	67
221	Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. <i>International Journal of Epidemiology</i> , 2014 , 43, 887-96	7.8	27
220	The IFNL3/4 Δ variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. <i>Aids</i> , 2014 , 28, 1885-9	3.5	34
219	Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals. <i>Antiviral Therapy</i> , 2014 , 19, 149-59	1.6	11
218	2014 Update of the drug resistance mutations in HIV-1. <i>Topics in Antiviral Medicine</i> , 2014 , 22, 642-50	3.2	160
217	Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation. <i>Retrovirology</i> , 2014 , 11, 75	3.6	12
216	Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. <i>Clinical Infectious Diseases</i> , 2013 , 57, 112-21	11.6	45
215	Expansion of interferon- β -secreting HIV-specific T cells during successful antiretroviral therapy. <i>HIV Medicine</i> , 2013 , 14, 241-6	2.7	5
214	Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. <i>Aids</i> , 2013 , 27, 203-10	3.5	19
213	The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients. <i>PLoS Computational Biology</i> , 2013 , 9, e1003203	5	17
212	24 hours in the life of HIV-1 in a T cell line. <i>PLoS Pathogens</i> , 2013 , 9, e1003161	7.6	101
211	Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. <i>Journal of Infectious Diseases</i> , 2013 , 207, 759-67	7	6
210	How effectively can HIV phylogenies be used to measure heritability?. <i>Evolution, Medicine and Public Health</i> , 2013 , 2013, 209-24	3	16
209	Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. <i>Journal of Infectious Diseases</i> , 2013 , 208, 1102-12	7	30
208	Early and nonreversible decrease of CD161 ⁺⁺ /MAIT cells in HIV infection. <i>Blood</i> , 2013 , 121, 951-61	2.2	237
207	Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 62, 28-35	3.1	74
206	Response to Calcagno comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid". <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 64, e14-5	3.1	1
205	Efavirenz intoxication due to a new CYP2B6 constellation. <i>Antiviral Therapy</i> , 2013 , 18, 739-43	1.6	5

204	Simple estimation of incident HIV infection rates in notification cohorts based on window periods of algorithms for evaluation of line-immunoassay result patterns. <i>PLoS ONE</i> , 2013 , 8, e71662	3.7	7
203	Next-generation sequencing of HIV-1 RNA genomes: determination of error rates and minimizing artificial recombination. <i>PLoS ONE</i> , 2013 , 8, e74249	3.7	47
202	Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study. <i>PLoS ONE</i> , 2013 , 8, e77691	3.7	35
201	Update of the drug resistance mutations in HIV-1: March 2013. <i>Topics in Antiviral Medicine</i> , 2013 , 21, 6-14,2	3.2	188
200	A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. <i>ELife</i> , 2013 , 2, e01123	8.9	85
199	Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 9-18	1.9	25
198	HLA-Bw4 identifies a population of HIV-infected patients with an increased capacity to control viral replication after structured treatment interruption. <i>HIV Medicine</i> , 2012 , 13, 589-95	2.7	2
197	Kommentar I zum Fall: Heimlicher Transfer von HIV-Medikamenten nach Afrika <i>Ethik in Der Medizin</i> , 2012 , 24, 59-61	0.5	
196	Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection. <i>BMC Infectious Diseases</i> , 2012 , 12, 88	4	11
195	Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells. <i>Retrovirology</i> , 2012 , 9, 27	3.6	36
194	Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. <i>PLoS ONE</i> , 2012 , 7, e37983	3.7	11
193	Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. <i>PLoS ONE</i> , 2012 , 7, e50307	3.7	14
192	A rare but severe pulmonary side effect of cetuximab in two patients. <i>BMJ Case Reports</i> , 2012 ,	0.9	12
191	Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 387-402	27.4	637
190	Estimating the basic reproductive number from viral sequence data. <i>Molecular Biology and Evolution</i> , 2012 , 29, 347-57	8.3	136
189	Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. <i>PLoS Pathogens</i> , 2012 , 8, e1002634	7.6	156
188	Inferring epidemic contact structure from phylogenetic trees. <i>PLoS Computational Biology</i> , 2012 , 8, e1002413	3.7	67
187	Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. <i>PLoS Pathogens</i> , 2012 , 8, e1002529	7.6	270

186	Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 2959-66	5.9	36
185	Role of retroviral restriction factors in the interferon- β -mediated suppression of HIV-1 in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 3035-40	11.5	107
184	Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. <i>Clinical Infectious Diseases</i> , 2012 , 54, 131-40	11.6	30
183	Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. <i>Clinical Infectious Diseases</i> , 2012 , 55, 1408-16	11.6	191
182	Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. <i>Aids</i> , 2012 , 26, 193-205	3.5	67
181	Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data. <i>Frontiers in Microbiology</i> , 2012 , 3, 329	5.7	167
180	Polymorphic mutations associated with the emergence of the multinucleoside/tide resistance mutations 69 insertion and Q151M. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 59, 105-12	3.1	6
179	Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy. <i>PLoS ONE</i> , 2012 , 7, e29186	3.7	21
178	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. <i>Lancet Infectious Diseases, The</i> , 2011 , 11, 363-71	25.5	292
177	Minority K65R variants and early failure of antiretroviral therapy in HIV-1-infected Eritrean immigrant. <i>Emerging Infectious Diseases</i> , 2011 , 17, 1966-8	10.2	8
176	A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. <i>PLoS ONE</i> , 2011 , 6, e27903	3.7	16
175	Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 57, 24-31	3.1	15
174	Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 58, 253-60	3.1	18
173	Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. <i>Antiviral Therapy</i> , 2011 , 16, 535-45	1.6	65
172	Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2011 , 12, 299-307	3.7	13
171	Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals—the Swiss HIV Cohort Study. <i>Journal of Translational Medicine</i> , 2011 , 9, 14	8.5	8
170	A Bayesian network approach to study host and viral genetic correlates of HIV-1 disease progression. <i>Retrovirology</i> , 2011 , 8, P70	3.6	1
169	Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. <i>Hepatology</i> , 2011 , 53, 1446-54	11.2	53

168	MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. <i>Journal of Experimental Medicine</i> , 2011 , 208, 439-54	16.6	87
167	Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. <i>Journal of Experimental Medicine</i> , 2011 , 208, 1419-33	16.6	82
166	No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipotrophy. <i>Journal of Infectious Diseases</i> , 2011 , 203, 620-4	7	10
165	Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study. <i>Journal of Infectious Diseases</i> , 2011 , 203, 791-7	7	8
164	The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. <i>Journal of Infectious Diseases</i> , 2011 , 204, 1095-103	7	60
163	Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. <i>Gut</i> , 2011 , 60, 1506-19	19.2	52
162	Assessing predicted HIV-1 replicative capacity in a clinical setting. <i>PLoS Pathogens</i> , 2011 , 7, e1002321	7.6	32
161	Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. <i>Clinical Infectious Diseases</i> , 2011 , 53, 1143-52	11.6	47
160	Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. <i>Clinical Infectious Diseases</i> , 2011 , 53, 1271-9	11.6	70
159	Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. <i>Journal of Infectious Diseases</i> , 2011 , 203, 246-57	7	80
158	Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. <i>Clinical Infectious Diseases</i> , 2011 , 52, 532-9	11.6	99
157	Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. <i>Journal of Clinical Investigation</i> , 2011 , 121, 2391-400	15.9	144
156	Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. <i>PLoS ONE</i> , 2011 , 6, e27463	3.7	41
155	2011 update of the drug resistance mutations in HIV-1. <i>Topics in Antiviral Medicine</i> , 2011 , 19, 156-64	3.2	193
154	Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 54, 197-203	3.1	83
153	Aortic homograft endocarditis caused by <i>Cardiobacterium hominis</i> and complicated by agranulocytosis due to ceftriaxone. <i>BMJ Case Reports</i> , 2010 , 2010,	0.9	3
152	Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. <i>Aids</i> , 2010 , 24, 2347-54	3.5	87
151	Host and viral genetic correlates of clinical definitions of HIV-1 disease progression. <i>PLoS ONE</i> , 2010 , 5, e11079	3.7	68

150	Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. <i>PLoS ONE</i> , 2010 , 5, e13310	3.7	72
149	Failure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infections. <i>Journal of Infectious Diseases</i> , 2010 , 202, 1482-5	7	37
148	Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase. <i>Journal of Infectious Diseases</i> , 2010 , 201, 1054-62	7	25
147	Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2010 , 201, 1063-71	7	46
146	Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. <i>Gut</i> , 2010 , 59, 1252-8	19.2	39
145	Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. <i>Journal of Infectious Diseases</i> , 2010 , 201, 1488-97	7	145
144	HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2010 , 51, 620-8	11.6	24
143	Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2010 , 202, 1553-61	7	218
142	Cohort profile: the Swiss HIV Cohort study. <i>International Journal of Epidemiology</i> , 2010 , 39, 1179-89	7.8	282
141	Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. <i>PLoS Pathogens</i> , 2010 , 6, e1001123	7.6	91
140	Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. <i>PLoS Pathogens</i> , 2010 , 6, e1000781	7.6	135
139	Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 321-33	27.4	677
138	Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 53, 464-71	3.1	16
137	Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. <i>Gastroenterology</i> , 2010 , 138, 1338-45, 1345.e1-7	13.3	956
136	Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study. <i>AIDS Research and Human Retroviruses</i> , 2010 , 26, 1239-46	1.6	4
135	Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. <i>Archives of Internal Medicine</i> , 2010 , 170, 410-9		35
134	HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. <i>Aids</i> , 2010 , 24, 1177-83	3.5	52
133	Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. <i>Aids</i> , 2010 , 24, 2451-60	3.5	185

132	Pulmonary toxoplasmosis, a rare but severe manifestation of a common opportunistic infection in late HIV presenters: report of two cases. <i>Infection</i> , 2010 , 38, 141-4	5.8	10
131	Hemophagocytic syndrome caused by primary herpes simplex virus 1 infection: report of a first case. <i>Infection</i> , 2010 , 38, 423-6	5.8	15
130	Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance. <i>Journal of Virological Methods</i> , 2010 , 165, 151-60	2.6	27
129	HIV-1 replication activates CD4+ T cells with specificities for persistent herpes viruses. <i>EMBO Molecular Medicine</i> , 2010 , 2, 231-44	12	13
128	Association between specific HIV-1 Env traits and virologic control in vivo. <i>Infection, Genetics and Evolution</i> , 2010 , 10, 365-72	4.5	2
127	Update of the drug resistance mutations in HIV-1: December 2010. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2010 , 18, 156-63		97
126	Effects of HIV type-1 immune selection on susceptibility to integrase inhibitor resistance. <i>Antiviral Therapy</i> , 2009 , 14, 953-64	1.6	4
125	Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. <i>Clinical Infectious Diseases</i> , 2009 , 48, 239-47	11.6	163
124	The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. <i>Aids</i> , 2009 , 23, 1415-23	3.5	91
123	Common genetic variation and the control of HIV-1 in humans. <i>PLoS Genetics</i> , 2009 , 5, e1000791	6	310
122	Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. <i>Clinical Infectious Diseases</i> , 2009 , 48, 979-87	11.6	41
121	HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia. <i>Clinical Infectious Diseases</i> , 2009 , 48, e117-20	11.6	21
120	Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity. <i>Virology</i> , 2009 , 387, 98-108	3.6	52
119	Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. <i>Hepatology</i> , 2009 , 49, 1069-82	11.2	115
118	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. <i>Hepatology</i> , 2009 , 50, 1017-29	11.2	50
117	Spontaneous splenic rupture as manifestation of the immune reconstitution inflammatory syndrome in an HIV type 1 infected patient with tuberculosis. <i>Infection</i> , 2009 , 37, 163-5	5.8	7
116	Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). <i>HIV Medicine</i> , 2009 , 10, 647-56	2.7	19
115	A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 1057-69	3.2	95

114	Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. <i>Lancet Infectious Diseases, The</i> , 2009 , 9, 409-17	25.5	187
113	In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 300-9	1.9	122
112	HIV sensitivity to neutralization is determined by target and virus producer cell properties. <i>Aids</i> , 2009 , 23, 1659-67	3.5	43
111	Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. <i>Antiviral Therapy</i> , 2009 , 14, 771-9	1.6	8
110	African descent is associated with slower CD4 cell count decline in treatment-naïve patients of the Swiss HIV Cohort Study. <i>Aids</i> , 2009 , 23, 1269-76	3.5	27
109	Divergent effects of cell environment on HIV entry inhibitor activity. <i>Aids</i> , 2009 , 23, 1319-27	3.5	26
108	Update of the drug resistance mutations in HIV-1: December 2009. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2009 , 17, 138-45		83
107	Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. <i>Retrovirology</i> , 2008 , 5, 107	3.6	37
106	Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. <i>Clinical Infectious Diseases</i> , 2008 , 47, 266-85	11.6	362
105	Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked. <i>Journal of Virology</i> , 2008 , 82, 3834-42	6.6	22
104	The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. <i>Journal of Infectious Diseases</i> , 2008 , 198, 864-7	7	85
103	Acute cytomegalovirus colitis presenting during primary HIV infection: an unusual case of an immune reconstitution inflammatory syndrome. <i>Clinical Infectious Diseases</i> , 2008 , 46, e38-40	11.6	14
102	In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. <i>Journal of Virology</i> , 2008 , 82, 1591-9	6.6	45
101	HIV rebounds from latently infected cells, rather than from continuing low-level replication. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 16725-30	11.5	224
100	Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1299-309	11.6	29
99	HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1921-5	11.6	24
98	Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. <i>Journal of Infectious Diseases</i> , 2008 , 197, 411-9	7	122
97	Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?. <i>Aids</i> , 2008 , 22, 2481-92	3.5	16

96	Antibody responses in primary HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2008 , 3, 45-51	4.2	16
95	Update of the drug resistance mutations in HIV-1: Spring 2008. <i>Top</i> , 2008 , 16, 62-8	1.3	68
94	Update of the Drug Resistance Mutations in HIV-1. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2008 , 16, 138-45		78
93	Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 81, 557-66	6.1	207
92	In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. <i>Journal of Virology</i> , 2007 , 81, 8793-808	6.6	77
91	Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression. <i>Journal of Virology</i> , 2007 , 81, 6742-51	6.6	99
90	HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. <i>PLoS Medicine</i> , 2007 , 4, e96	11.6	65
89	Positive in vivo selection of the HIV-1 envelope protein gp120 occurs at surface-exposed regions. <i>Journal of Infectious Diseases</i> , 2007 , 196, 313-20	7	29
88	Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. <i>Aids</i> , 2007 , 21, 2223-9	3.5	100
87	Precise identification of a human immunodeficiency virus type 1 antigen processing mutant. <i>Journal of Virology</i> , 2007 , 81, 2031-8	6.6	26
86	Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients. <i>Journal of Infectious Diseases</i> , 2007 , 196, 1180-90	7	11
85	Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. <i>Archives of Internal Medicine</i> , 2007 , 167, 1782-90		95
84	Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes. <i>Journal of Virology</i> , 2007 , 81, 9693-706	6.6	60
83	Persistence of lamivudine-sensitive HIV-1 quasispecies in the presence of lamivudine in vitro and in vivo. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 44, 377-85	3.1	10
82	Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. <i>Aids</i> , 2007 , 21, 2201-7	3.5	6
81	Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure. <i>PLoS ONE</i> , 2007 , 2, e173	3.7	24
80	Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART. <i>Journal of Medical Virology</i> , 2006 , 78, 1003-10	19.7	36
79	HIV replication elicits little cytopathic effects in vivo: analysis of surrogate markers for virus production, cytotoxic T cell response and infected cell death. <i>Journal of Medical Virology</i> , 2006 , 78, 1141-8	19.7	12

78	Genetic attributes of cerebrospinal fluid-derived HIV-1 env. <i>Brain</i> , 2006 , 129, 1872-83	11.2	87
77	Equal amounts of intracellular and virion-enclosed hepatitis C virus RNA are associated with peripheral-blood mononuclear cells in vivo. <i>Journal of Infectious Diseases</i> , 2006 , 194, 1713-23	7	24
76	Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. <i>PLoS Medicine</i> , 2006 , 3, e441	11.6	79
75	Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAB 2G12) and gp41 (MAbs 4E10 and 2F5). <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 1773-9	5.9	56
74	Stable virulence levels in the HIV epidemic of Switzerland over two decades. <i>Aids</i> , 2006 , 20, 889-94	3.5	45
73	Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. <i>Aids</i> , 2006 , 20, 35-40	3.5	45
72	A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?. <i>Antiviral Therapy</i> , 2006 , 11, 305-14	1.6	4
71	A Longitudinal Analysis of Healthcare Costs after Treatment Optimization following Genotypic Antiretroviral Resistance Testing: Does Resistance Testing pay off?. <i>Antiviral Therapy</i> , 2006 , 11, 305-314	1.6	5
70	Biphasic decline of CD4 cell count during scheduled treatment interruptions. <i>Aids</i> , 2005 , 19, 439-41	3.5	20
69	HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 40, 250-6	3.1	21
68	Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. <i>Nature Medicine</i> , 2005 , 11, 615-22	50.5	419
67	Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. <i>Journal of Virology</i> , 2005 , 79, 9026-37	6.6	39
66	Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. <i>Journal of Virology</i> , 2005 , 79, 1772-88	6.6	119
65	Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring?. <i>Clinical Infectious Diseases</i> , 2005 , 41, 721-8	11.6	29
64	Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. <i>Journal of Virology</i> , 2005 , 79, 8454-69	6.6	70
63	Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. <i>Journal of Infectious Diseases</i> , 2005 , 191, 1410-8	7	252
62	Efavirenz intoxication due to slow hepatic metabolism. <i>Clinical Infectious Diseases</i> , 2005 , 40, e22-3	11.6	61
61	Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. <i>Journal of Infectious Diseases</i> , 2005 , 192, 1381-6	7	163

60	Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. <i>Clinical Infectious Diseases</i> , 2005 , 40, e120-4	11.6	40
59	Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef. <i>Journal of Infectious Diseases</i> , 2004 , 190, 1979-88	7	49
58	Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 12266-70	11.5	71
57	Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection. <i>Journal of Virology</i> , 2004 , 78, 10747-54	6.6	41
56	Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. <i>Aids</i> , 2004 , 18, 1951-3	3.5	64
55	Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2004 , 189, 273-85	7	33
54	Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. <i>Virology</i> , 2004 , 326, 113-29	3.6	66
53	Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV Cohort Study: a nested case-control study. <i>AIDS Research and Human Retroviruses</i> , 2004 , 20, 909-15	1.6	24
52	Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. <i>Blood</i> , 2004 , 104, 1784-92	2.2	42
51	Effect of Individual Cognitive Behaviour Intervention on Adherence to Antiretroviral Therapy: Prospective Randomized Trial. <i>Antiviral Therapy</i> , 2004 , 9, 85-95	1.6	43
50	Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 4819-24	11.5	210
49	Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. <i>Journal of Infectious Diseases</i> , 2003 , 188, 1433-43	7	114
48	HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 33, 292-9	3.1	35
47	A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART. <i>Aids</i> , 2003 , 17, 1487-92	3.5	19
46	HIV RNA in plasma rebounds within days during structured treatment interruptions. <i>Aids</i> , 2003 , 17, 195-9.5	3.5	59
45	A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. <i>Archives of Internal Medicine</i> , 2003 , 163, 1220-6		129
44	Aortic homograft endocarditis caused by <i>Rhodotorula mucilaginosa</i> . <i>Infection</i> , 2003 , 31, 181-3	5.8	20
43	Gonococcal tonsillar infection--a case report and literature review. <i>Infection</i> , 2003 , 31, 362-5	5.8	17

42	Glancing behind virus load variation in HIV-1 infection. <i>Trends in Microbiology</i> , 2003 , 11, 499-504	12.4	51
41	Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection. <i>Journal of Virology</i> , 2003 , 77, 13146-55	6.6	50
40	Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo. <i>Antiviral Therapy</i> , 2003 , 8, 97-104	1.6	13
39	Drug resistance mutations during structured treatment interruptions. <i>Antiviral Therapy</i> , 2003 , 8, 411-5	1.6	10
38	Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. <i>Antiviral Therapy</i> , 2003 , 8, 443-54	1.6	8
37	Shifts in Cell-Associated HIV-1 Rna but Not in Episomal HIV-1 Dna Correlate with New Cycles of HIV-1 Infection in vivo. <i>Antiviral Therapy</i> , 2003 , 8, 97-104	1.6	14
36	Drug Resistance Mutations during Structured Treatment Interruptions. <i>Antiviral Therapy</i> , 2003 , 8, 411-415	1.6	19
35	Impact of Genotypic Resistance Testing on Selection of Salvage Regimen in Clinical Practice. <i>Antiviral Therapy</i> , 2003 , 8, 443-454	1.6	18
34	Functional discrepancies in HIV-specific CD8+ T-lymphocyte populations are related to plasma virus load. <i>Journal of Clinical Immunology</i> , 2002 , 22, 363-74	5.7	31
33	Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load. <i>Aids</i> , 2002 , 16, 2317-22	3.5	17
32	Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. <i>Journal of Virology</i> , 2002 , 76, 10169-76	6.6	40
31	Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 13747-52	11.5	176
30	A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. <i>Journal of Infectious Diseases</i> , 2002 , 185, 1251-60	7	121
29	Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. <i>Aids</i> , 2002 , 16, 1967-9	3.5	88
28	Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts. <i>Antiviral Therapy</i> , 2002 , 7, 91-103	1.6	34
27	Residual Cell-Associated Unspliced HIV-1 Rna in Peripheral Blood of Patients on Potent Antiretroviral Therapy Represents Intracellular Transcripts. <i>Antiviral Therapy</i> , 2002 , 7, 91-103	1.6	38
26	Direct ex vivo analysis reveals distinct phenotypic patterns of HIV-specific CD8(+) T lymphocyte activation in response to therapeutic manipulation of virus load. <i>European Journal of Immunology</i> , 2001 , 31, 1115-21	6.1	26
25	Evidence for positive selection driving the evolution of HIV-1 env under potent antiviral therapy. <i>Virology</i> , 2001 , 284, 250-8	3.6	42

24	Quantification of In Vivo Replicative Capacity of HIV-1 in Different Compartments of Infected Cells. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 26, 397-404	3.1	12
23	Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 26, 397-404	3.1	43
22	Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. <i>Journal of Infectious Diseases</i> , 2001 , 183, 1318-27	7	125
21	Prevalence and predictive value of intermittent viremia with combination hiv therapy. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 286, 171-9	27.4	256
20	Liver failure after long-term nucleoside antiretroviral therapy. <i>Lancet, The</i> , 2001 , 358, 759-60	40	10
19	Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy. <i>Aids</i> , 2000 , 14, 31-6	3.5	147
18	Impact of TNFalpha, LTalpha, Fc gammaRII and complement receptor on HIV-1 trapping in lymphoid tissue from HIV-infected patients. <i>Aids</i> , 2000 , 14, 2661-9	3.5	4
17	Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2000 , 16, 1135-40	1.6	45
16	Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2000 , 181, 522-31	7	102
15	Antiretroviral resistance during successful therapy of HIV type 1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 10948-53	11.5	188
14	Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection. <i>American Journal of Pathology</i> , 2000 , 156, 1973-86	5.8	34
13	Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 1999 , 180, 1043-9	7	14
12	Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 5169-72	11.5	65
11	Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV-1 pol. <i>Virology</i> , 1999 , 259, 154-65	3.6	30
10	Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. <i>AIDS Research and Human Retroviruses</i> , 1998 , 14, 869-76	1.6	130
9	Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. <i>Science</i> , 1997 , 278, 1291-5	33.3	1754
8	Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 12574-9	11.5	207
7	Analysis of restriction fragment length polymorphism and ribotyping of multiresistant <i>Stenotrophomonas maltophilia</i> isolated from persisting lung infection in a cystic fibrosis patient. <i>Scandinavian Journal of Infectious Diseases</i> , 1995 , 27, 499-502		12

6	Pharmacokinetics of an HIV-1 gp120-specific chimeric antibody in patients with HIV-1 disease. <i>Biotherapy (Dordrecht, Netherlands)</i> , 1993 , 6, 205-15	5
5	Easy and Accurate Reconstruction of Whole HIV Genomes from Short-Read Sequence Data	4
4	Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C	2
3	High efficacy of saliva in detecting SARS-CoV-2 by RT-PCR in adults and children	2
2	Multifactorial SARS-CoV-2 seroprofiling dissects interdependencies with human coronaviruses and predicts neutralization activity	2
1	Contribution of endogenous and exogenous antibodies to clearance of SARS-CoV-2 during convalescent plasma therapy	2